SRBCF Sirona Biochem Corp (PK)

VANCOUVER, BC--(Marketwired - April 03, 2014) - Sirona Biochem Corp. (TSX-VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) is pleased to announce that it will be hosting a webinar to provide direct access to the leadership team of Sirona Biochem for questions and answers. The discussion will be moderated by Neil Belenkie, CEO of Sirona Biochem.

Details:

Date: Tuesday, April 15 2014 Time: 2pm - 3pm PDT Register for Access: https://attendee.gotowebinar.com/register/4868347574215913729

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

For more information regarding this press release, contact: Christopher HoptonCFOSirona Biochem Corp. Phone: 1.604.282.6064Email: chopton@sironabiochem.com

Sirona Biochem (PK) (USOTC:SRBCF)
Historical Stock Chart
From Nov 2024 to Dec 2024

Sirona Biochem (PK) (USOTC:SRBCF)
Historical Stock Chart
From Dec 2023 to Dec 2024